Study to Assess Safety and Effectiveness of Branebrutinib Treatment in Participants With Active Systemic Lupus Erythematosus or Primary Sjögren's Syndrome, or Branebrutinib Treatment Followed by Open-label Abatacept Treatment in Study Participants With Active Rheumatoid Arthritis

Inclusion Criteria

• •Sub-study for Systemic Lupus Erythematosus (SLE)
• •Active SLE as defined by the Systemic Lupus Erythematosus International Collaborating Clinics (SLICC) classification
• •Diagnosed with SLE more than 24 weeks before screening visit
• •Sub-study for primary Sjögren's Syndrome (pSS)
• •Moderate to severe pSS, meeting ACR-EULAR classification criteria
• •Sub-study for active Rheumatoid Arthritis (RA)
• •Moderate to severe adult-onset RA
• •ACR global functional status class I to III
• •Women and men must agree to follow instructions for methods of contraception.